Data from: <b>Selection and genetic variation in plasticity drive age-related decreases in among-individual behavioural correlations</b> by Chang Seok Han (21814121)

“…Our findings indicate that the magnitudes of both the positive among-individual and genetic correlations were maintained across nymph and young adult stages, but significantly decreased with age during adulthood. This decrease was due to both selection and genetic variation in age-related behavioural plasticity. …”

Original data2. by Lan Zeng (638254)

“…<div><p>Diabetic retinopathy (DR) is a leading cause of blindness. We hypothesised that the long non-coding RNA <i>RP11-502I4.3</i> may be involved in angiogenesis associated with DR. …”

Original data1. by Lan Zeng (638254)

“…<div><p>Diabetic retinopathy (DR) is a leading cause of blindness. We hypothesised that the long non-coding RNA <i>RP11-502I4.3</i> may be involved in angiogenesis associated with DR. …”

Data Sheet 1_Dihydroartemisinin decreases pre-existing neutralizing antibodies against adeno-associated virus in challenged mice.pdf by Jingjing Fang (124938)

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Ischemic heart disease-related mortality trends in older adult population and stratified for census regions in 1999–2020. by Fakhar Latif (19760906)

Subjects:

Cases and age-standardized rates of hematological malignancies in mainland China and their temporal trends. by Yu Fu (16582)

Subjects:

Projections of incidence for hematological malignancies in mainland China. by Yu Fu (16582)

Subjects:

Ischemic heart disease-related mortality trends in older adult population and stratified for metropolitan vs. non-metropolitan in 1999–2020. by Fakhar Latif (19760906)

Subjects:

Age- and sex-specific distribution of prevalence, incidence, mortality, and DALY rates for lymphoma, multiple myeloma, and other hematological neoplasms in mainland China. by Yu Fu (16582)

Subjects:

Disease burden trends of leukemia and lymphoma analyzed by joinpoint regression analysis in mainland China. by Yu Fu (16582)

Subjects:

Ischemic heart disease-related mortality trends in older adult population and stratified for gender in 1999–2020. by Fakhar Latif (19760906)

Subjects:

Disease burden trends of multiple myeloma and other hematological neoplasms analyzed by joinpoint regression analysis in mainland China. by Yu Fu (16582)

Subjects:

Ischemic heart disease-related mortality trends in older adult population and stratified for older vs. young population in 1999–2020. by Fakhar Latif (19760906)

Subjects:

Cases and age-standardized rates of hematological malignancies in Taiwan and their temporal trends. by Yu Fu (16582)

Subjects:

The raw data used in this study. by Yu Fu (16582)

Subjects:

Deaths, overall AAMRs, and Annual Percent Change (APC) of ischemic heart diseases-related mortality in older adults in the United States, 1999 to 2020. by Fakhar Latif (19760906)

Subjects:

Ischemic heart disease-related mortality trends in older adult population and stratified for causes in 1999–2020. by Fakhar Latif (19760906)

Subjects: